目次

Table of Content

1. RESEARCH METHODOLOGY

2. Introduction To RNA Polymerase I
2.1 Brief Overview Of RNA Polymerase I and Biological Role
2.2 Importance Of Nucleolar Stress and Ribosomal Biogenesis In Oncogenesis

3. Mechanistic Basis For Targeting RNA Polymerase I
3.1 Rationale For Targeting RNA Pol I
3.2 Direct Pol I Inhibition vs Indirect Modulation

4. Approaches To Target RNA Polymerase I
4.1 Small Molecule Inhibitors
4.2 Polypharmacology

5. Disease Areas Of Interest For RNA Polymerase I Inhibition
5.1 Oncology
5.1.1 Hematological Malignancies
5.1.2 Solid Tumors
5.2 Emerging Indications

6. RNA Polymerase I Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase
6.1 Research
6.2 Phase I
6.3 Phase II

7. Global RNA Polymerase I Inhibitors Market Overview
7.1 Current Market Scenario
7.2 Future RandD and Commercial Opportunities

8. RNA Polymerase I Inhibitors Market Dynamics
8.1 Drivers and Opportunities
8.2 Challenges and Restraints

9. Competitive Landscape
9.1 Pimera
9.2 Senhwa Biosciences

List of Figures & Tables
Figure 2-1: RNA Pol I Transcription and rRNA Processing Pathway
Figure 2-2: Regulation of RNA Pol I Transcription
Figure 2-3: RNA Pol I Activity During Cell Cycle
Figure 2-4: Nucleolar Stress and p53 Activation
Figure 2-5: Pol I - Therapeutic Inhibition in Cancer
Figure 2-6: CX-5461 and BMH-21 - Mechanisms Of Action
Figure 2-7: Nucleolus - Functions
Figure 2-8: Ribosome Biogenesis - Normal vs Cancer Cell
Figure 2-9: Cancer Addiction To RNA Polymerase I
Figure 3-1: Cellular Response To Pol I Inhibition
Figure 3-2: Direct Pol I Inhibition
Figure 3-3: Indirect Pol I Inhibition
Figure 3-4: Consequences Of Pol I Transcription Inhibition
Figure 4-1: Small Molecule Pol I Inhibitors - Advantages
Figure 4-2: Polypharmacology In Cancer Treatment
Figure 5-1: Hematological Malignancies - Mechanism Of Action of Pol I Inhibition
Figure 5-2: NCI-2025-04787 Phase 1/2 (NCT07069699) Study - Initiation and Completion Year
Figure 5-3: CX-5461-04 Phase 1 (NCT04890613) Study - Initiation and Completion Year
Figure 5-4: NCI-2024-07701 Phase 1 (NCT06606990) Study - Initiation and Completion Year
Figure 7-1: Global RNA Polymerase I Inhibitors Market - Future Opportunities
Figure 8-1: Global RNA Polymerase I Inhibitors Market - Drivers and Opportunities
Figure 8-2: Global RNA Polymerase I Inhibitors Market - Key Challenges and Strategic Solutions
Table 3 1: RNA Polymerase I - Direct Inhibition v/s Indirect Modulation
Table 4 1: Chemotherapeutic Drugs With Polypharmacologic Activity On Pol I
Table 6 1: RNA Polymerase I Inhibitors In Research Phase